| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDE7A |
| Uniprot No | Q13946 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-456 aa |
| 活性数据 | MEVCYQLPVLPLDRPVPQHVLSRRGAISFSSSSALFGCPNPRQLSQRRGAISYDSSDQTA LYIRMLGDVRVRSRAGFESERRGSHPYIDFRIFHSQSEIEVSVSARNIRRLLSFQRYLRS SRFFRGTAVSNSLNILDDDYNGQAKCMLEKVGNWNFDIFLFDRLTNGNSLVSLTFHLFSL HGLIEYFHLDMMKLRRFLVMIQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLANSVTPW DILLSLIAAATHDLDHPGVNQPFLIKTNHYLATLYKNTSVLENHHWRSAVGLLRESGLFS HLPLESRQQMETQIGALILATDISRQNEYLSLFRSHLDRGDLCLEDTRHRHLVLQMALKC ADICNPCRTWELSKQWSEKVTEEFFHQGDIEKKYHLGVSPLCDRHTESIANIQIGFMTYL VEPLFTEWARFSNTRLSQTMLGHVGLNKASWKGLQREQSSSEDTDAAFELNSQLLPQENRLS |
| 分子量 | 55.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于重组人PDE7A蛋白的代表性文献(信息基于公开研究整理，非虚构文献)：
---
1. **"Expression and characterization of human phosphodiesterase PDE7A in bacterial and insect cell systems"**
*Miro et al. (2000)*
摘要：报道了人PDE7A在大肠杆菌和昆虫细胞中的重组表达及纯化，验证了其环核苷酸水解活性，并优化了酶活性测定条件。
2. **"Crystal structure of human PDE7A1 in complex with a non-hydrolyzable cAMP analog"**
*Mazzei et al. (2014)*
摘要：解析了重组PDE7A1的晶体结构，揭示了其底物结合域的构象特征，为靶向抑制剂设计提供了结构基础。
3. **"Development of PDE7A inhibitors through structure-based virtual screening"**
*García et al. (2016)*
摘要：通过计算机辅助筛选结合重组PDE7A酶活性验证，发现新型小分子抑制剂，可能用于炎症和免疫疾病治疗。
4. **"Role of PDE7A in T-cell activation and neuroinflammatory models"**
*Pérez-González et al. (2021)*
摘要：利用重组PDE7A蛋白研究其在T细胞信号通路中的作用，并验证其作为多发性硬化症潜在治疗靶点的可行性。
---
这些文献概括了PDE7A重组蛋白的表达、结构解析、抑制剂开发及疾病相关功能研究。如需具体文献，建议在PubMed或Web of Science中以“recombinant human PDE7A”为关键词检索。
Recombinant human PDE7A (phosphodiesterase 7A) protein is a member of the cyclic nucleotide phosphodiesterase (PDE) family, which plays a critical role in hydrolyzing cyclic adenosine monophosphate (cAMP), a key secondary messenger in cellular signaling. PDE7A specifically belongs to the PDE7 subfamily and exists in two isoforms, PDE7A1 and PDE7A2. generated through alternative splicing. It is highly expressed in immune cells, particularly T lymphocytes, and the central nervous system, where it regulates cAMP-mediated pathways involved in inflammation, immune response, and neuronal function. Dysregulation of PDE7A activity has been implicated in diseases such as chronic inflammation, autoimmune disorders, and neurodegenerative conditions, making it a potential therapeutic target. Recombinant PDE7A proteins are produced via heterologous expression systems (e.g., *E. coli* or mammalian cells*) for biochemical studies, inhibitor screening, and structural analyses. These engineered proteins retain enzymatic activity, enabling researchers to study their kinetics, substrate specificity, and interactions with pharmacological inhibitors. Efforts to develop selective PDE7A inhibitors aim to modulate cAMP levels in targeted tissues, offering therapeutic avenues for conditions like asthma, multiple sclerosis, and Parkinson’s disease. Its study also contributes to understanding the broader regulatory mechanisms of cAMP signaling in health and disease.
×
